Introduction
Interleukin (IL)-18, a member of the IL-1 superfamily, is a proinflammatory cytokine produced by a wide range of cells including monocytes/macrophages, T and B cells, dendritic cells and epithelial cells (Dinarello, 1999; Gardella et al., 1999 Gardella et al., , 2000 Naik et al., 1999) . IL-18 shares some biological properties with IL-12 (Trinchieri, 2003) , such as induction of interferon gamma (IFN g) secretion by T cells, enhancement of natural killer cell cytotoxicity and stimulation of Th1 cell differentiation (Okamura et al., 1995; Ushio et al., 1996; Kohno et al., 1997; Takeda et al., 1998) .
Similar to IL-1b, IL-18 is synthesized as an inactive precursor protein of 24 kDa lacking a typical signal peptide (pro-IL-18). Pro-IL-18 is mainly processed to a mature and bioactive molecule (mat-IL-18) of 18 kDa by the intracellular cysteine proteinase caspase-1 (Ghayur et al., 1997; . Pro-IL-18 is substrate of other proteases able to generate both the biologically active form of the cytokine (caspase-4) (Nakanishi et al., 2001) or an inactive molecule of 14 kDa (caspase-3) (Akita et al., 1997; Gu et al., 1997; Nakanishi et al., 2001) . IL-18 is released from cells both as the 18 kDa mature form and as the inactive precursor molecule. In addition, extracellular cleavage of pro-IL-18 by different proteases such as granulocyte proteinase-3 has been reported Sugawara et al., 2001) .
In a previous study we showed, by the analysis of a large series of ovarian carcinoma cell lines and fresh tumor samples, that these tumors frequently express IL-18, while in the same cells the expression of caspase-1 is more variable. Nevertheless, tumors, which showed coexpression of IL-18 and caspase-1, also did not reveal the presence of detectable mat-IL-18 protein in lysates or supernatants. On the contrary, we found coexpression of IL-18 and caspase-1 in all normal ovarian epithelial cell samples analysed. In addition, we could detect the presence of biologically active mat-IL-18 in the concentrated culture supernatants of these normal cells (Wang et al., 2002) . These data suggested that the defective processing of IL-18 is restricted to tumor cells and may possibly relate to the oncogenic process. Other authors proposed that loss of IL-18 processing may occur also in colon carcinoma, which frequently showed loss of caspase-1 expression (Pages et al., 1999) . Production of IL-18 appeared a common feature not only of normal colon (Kalina et al., 2002) and ovarian epithelium (Wang et al., 2002) but also of several other surface epithelia, such as keratinocytes (Stoll et al., 1997; Naik et al., 1999) , oral (Sugawara et al., 2001) and airway epithelial cells (Cameron et al., 1999) , where it may play an important role in the defense from pathogens (Lu et al., 2000) .
In the present study, we first show that a fraction of pro-IL-18 extracted from ovarian carcinoma cell lines appeared to be resistant to 'in vitro' processing by recombinant caspase-1. Cloning and sequence analysis of pro-IL-18 cDNA from one of these cell lines revealed the existence of a novel alternatively spliced variant of IL-18 mRNA, which lacked exon-3 (D3pro-IL-18). The D3pro-IL-18 protein expressed upon transfection into a murine cell line was resistant to proteolytic activation by caspase-1 or -4, although it was still capable to bind caspase-1. Thus, exon-3 alternative splicing may downregulate biologically active IL-18 production.
Results
Analysis of IL-18 and caspase-1, -3 and -4 gene expression in human ovarian carcinoma cell lines
We first analysed the expression of caspase-1, -3 and -4, mRNA in four different ovarian cancer cell lines which displayed a clear positivity for IL-18 mRNA ( Figure 1a ) and which were known, from a previous study, to accumulate a significative amount of intracellular pro-IL-18 protein, detectable by Western blot analysis (Wang et al., 2002) . All these ovarian cancer cell lines displayed amplification products of the expected size for caspase-3 (362 bp) and -4 (456 bp). On the contrary, caspase-1 (842 bp) was detectable only in two (A2780, OVCAR-3) out of four cell lines analysed.
Two different ovarian cancer cell lines, IGROV-1 and OVCAR-3, which were negative and positive for caspase-1 expression, respectively, were selected for further studies. Western blot analysis on their cell lysates showed a band corresponding to intracellular pro-IL-18 (24 kDa) in both samples analysed, while the mature form of the cytokine (18 kDa) was not detectable in cell lysates (Figure 1b untreated samples) and in concentrated cell culture supernatants (Wang et al., 2002) . In addition, we could visualize two bands corresponding to caspase-1 protein (p45 and p20) in OVCAR-3 cell line lysate, but not in IGROV-1 (Wang et al., 2002) .
Evidence for a pro-IL-18 protein resistant to caspase-1 processing Since the use of different stimuli capable to activate different caspases, such as LPS, g or UV-irradiation, and CD95 triggering failed to activate the processing of intracellular pro-IL-18 in OVCAR-3 and IGROV-1 cell lines (data not shown and Wang et al., 2002) , we tested whether pro-IL-18 present in these samples was really susceptible to processing by caspase-1. To this end we performed an 'in vitro' digestion of OVCAR-3 and IGROV-1 cell lysates with different amounts of recombinant caspase-1.
As shown in Figure 1b , Western blot analysis of recombinant caspase-1-treated lysates revealed a partial digestion of intracellular pro-IL18, both in OVCAR-3 and IGROV-1 cell lines. Thus, a band corresponding to mat-IL-18 (18 kDa) was observed, together with an evident band of unprocessed pro-IL-18. Also, the use of high concentration of recombinant caspase-1 (100 U) did not allow to achieve a complete processing of pro-IL-18 in these cell lysates. Indeed with 100 U of recombinant caspase-1, only 50% of pro-IL-18 was cleaved to mat-IL-18 in the OVCAR-3 cell lysate.
Cloning and sequence analysis of pro-IL-18 cDNA from OVCAR-3 cell line reveals the presence of an alternative transcript To assess whether undigested intracellular pro-IL-18 from OVCAR-3 cell line could represent a peculiar Caspase-1 and -4-resistant variant of pro-IL-18 A Gaggero et al molecular form of IL-18, we performed RT-PCR on total OVCAR-3 RNA using specific oligonucleotide primers allowing the amplification of the whole ORF of the pro-IL-18. The amplification products (593 bp), which appeared as a single band after standard 1% agarose electrophoresis analysis, were cloned in the pCR2.1 plasmid vector and five different clones were sequenced using specific M13 primers. Analysis of the five sequences showed the existence of two different cDNAs, characterized by the presence (3/5), as in the already described pro-IL-18 cDNA, or the absence (2/5), of a 12 bp sequence, suggesting the existence of two different transcripts of pro-IL-18.
As shown in Figure 2a , the human IL-18 gene is composed by six different exons (Kalina et al., 2000) . The 12 bp sequence corresponds to exon 3. Thus, a novel alternative transcript (D3pro-IL-18) is generated by splicing out exon 3, and the predicted protein would lack the amino-acidic sequence 'AEDD'. Since the caspase-1 and -4 cleavage site is located in the sequence encoded by exon 4 of IL-18, this site is maintained also in the predicted D3pro-IL-18 protein (Figure 2a ). RT-PCR analysis of classical and D3pro-IL-18 mRNA isoforms in total RNA extracted from different cell lines. Schematic representation of the two specific primers designed to allow amplification of a short cDNA fragment of IL-18 flanking exon-3, of either 87 or 75 bp for the classical and the D3pro-IL-18 mRNA isoform, respectively, is shown. Amplification products were analysed on 4% agarose gels. Southern blotting of the amplification products and hybridization with probes specific for both (on/off), or for only the classical (on) or only the D3pro-IL-18 (off). A schematic representation of different probes used for probing the southern membrane is shown
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RT-PCR analysis of IL-18 isoforms expression in different cell lines
To gain more information on the expression of this novel IL-18 transcript, we performed, on four different ovarian cancer cell lines, RT-PCR analysis using oligonucleotide primers which allow amplification of a short cDNA fragment including the region containing exon-3. By the use of these specific primers, we expected two amplification products of 87 and 75 bps corresponding to the classical and to the D3pro-IL-18, respectively. Separation of these amplification products on 4% agarose gel produced two bands of the expected size in 4/4 ovarian carcinoma cell lines (Figure 2b ). Although the relative abundancy of the two amplification products varied consistently in the different cell lines analysed, a predominance of the 'classical' transcript was observed. Southern blots analysis of the above amplification products with oligonucleotide probes specific for the classical, or for the D3pro-IL-18, or hybridizing to both cDNAs confirmed the specificity of the two bands ( Figure 2b ). In addition, D3pro-IL-18 mRNA was detectable in 3/3 fresh tumor cell samples, isolated from the ascitic fluid of ovarian carcinoma patients (Figure 3a) .
We further analysed whether the novel transcript was also expressed in normal ovarian surface epithelial cells, which we have previously shown to express IL-18 and caspase-1, and to be capable to process IL-18 to its mature form (Wang et al., 2002) . We were unable to detect the D3pro-IL-18 transcript by RT-PCR analysis in 4/4 samples analysed, suggesting that this transcript is expressed by ovarian carcinoma cells but not in the normal cellular counterpart (Figure 3b ).
Expression of D3pro-IL-18 protein by gene transfection
To characterize the D3pro-IL-18 protein, we subcloned the classical or D3pro-IL-18 cDNA into the pIRES1neo expression plasmid. Stable transfectants of the murine Neuro2a cell line, expressing either the classical or D3pro-IL-18 transcripts were obtained (Figure 4a ). Western blot analysis of cell lysates of these tranfectants revealed synthesis of both pro-IL-18 protein isoforms, which in view of the minimal difference in size (4 aa) showed a similar electrophoretic mobility on 14% SDS-PAGE analysis. Both the isoforms were detectable in the concentrated culture supernatants as pro-IL-18 form, suggesting that both can be released from cells in low amounts as unprocessed proteins (Figure 4b ).
Altered sensitivity of D3pro-IL-18 to caspase-1 and -4 cleavage
Although the cleavage site of caspase-1 was retained in D3pro-IL-18, the finding of a residual unprocessed IL-18 in IGROV-1 and OVCAR-3 lysates after digestion with caspase-1 suggested that expression of D3pro-IL-18 Caspase-1 and -4-resistant variant of pro-IL-18 A Gaggero et al could account for this observation. To test this hypothesis, we treated cell lysates of Neuro2a cell transfectants, expressing either one isoform of pro-IL-18, with different concentrations of caspase-1 ranging from 10 to 100 U and then verified the processing by Western blot analysis.
As shown in Figure 5 , a band of 18 kDa corresponding to the size of mat-IL-18 was detectable in the digested lysate of Neuro2a, expressing the classical pro-IL-18. The amount of mat-IL-18 increased with dependency on the concentration of caspase-1, and processing was complete using 100 U of caspase-1, where a complete disappearance of the 24 kDa pro-IL-18 was observed. By contrast D3pro-IL-18, under the same experimental conditions, showed a complete resistance to caspase-1 processing, and no mat-IL-18 was detected. D3pro-IL-18 was also resistant to processing by caspase-4 at concentrations (100 U) that were capable to cleave the classical pro-IL-18 isoform to mat-IL-18, although at the highest concentration of caspase-4 (500 U) D3pro-IL-18 was cleaved to a fragment of about 14 kDa, corresponding to an inactive cleavage product. Caspase-3 cleaved both the classical and the D3pro-IL-18 to a 14 kDa inactive fragment. These data show that the molecular variant D3pro-IL-18 is resistant to activation by caspase-1 and -4, but sensitive to cleavage by caspase-3 to an inactive fragment.
D3pro-IL-18 is able to bind caspase-1
Since D3pro-IL-18 maintains the cleavage site of caspase-1 it is possible that it binds to caspase-1 and possibly acts as a competitive inhibitor of classical pro-IL-18 processing. To test the ability of D3pro-IL-18 to bind to caspase-1, the cell lysate of Neuro2a cells expressing D3pro-IL-18 was incubated in the presence or absence of human recombinant caspase-1, and complexes were immunoprecipitated using an anti-IL-18 polyclonal rabbit anti-serum and sepharose-protein-A. Staining of Western blots of immunoprecipitated molecules with an anti-caspase-1 goat anti-serum revealed a specific band corresponding to the recombinant human caspase-1 only in the immunoprecipated molecules from the mixture of D3pro-IL-18 with caspase-1. Probing of a parallel Western blot with an anti-IL-18 mAb showed the 24 kDa band corresponding to D3pro-IL-18, irrespective of the presence or absence of caspase-1 (Figure 6 ). These data indicate that D3pro-IL-18 is capable to form complexes with active human caspase-1. 
Caspase-1 and -4-resistant variant of pro-IL-18
Discussion
In this study, we show that ovarian carcinoma cell lines express an alternatively spliced variant of IL-18 mRNA which lacks exon-3. The D3pro-IL-18 protein lacks the four amino-acid sequence AEDD, N-terminal to the site cleaved by caspase-1 and -4, which are responsible for the generation of the 18 kDa bioactive mature form of IL-18 (Ghayur et al., 1997; . However, recombinant caspase-1 or -4 were unable to process the D3pro-IL-18 in vitro to its mature form, whereas this isoform was cleaved to an inactive 14 kDa product by caspase-3. In a previous study, we showed that normal ovarian surface epithelial cells have the capability to process pro-IL-18 and to release biologically active IL-18 in culture supernatants, while ovarian carcinoma cell lines showed a defective processing (Wang et al., 2002) . The present finding that the intracellular pro-IL-18 from some ovarian carcinoma cell lines was partially resistant to recombinant caspase-1 and -4 cleavage in vitro suggested the presence of an altered pro-IL-18 form in these tumors, and led us to the discovery of D3pro-IL-18. Interestingly, the D3pro-IL-18 mRNA was undetectable in cultured normal ovarian epithelial cells, suggesting that the presence of the D3pro-IL-18 isoform could be related to neoplastic transformation of these cells. In human tumors, the processing of several mRNA is altered, thus generating alternative transcripts that have been associated to malignant transformation. In particular, this is the case of tumor-associated isoforms of the extracellular matrix proteins fibronectin (Nicolo et al., 1999) and tenascin (Carnemolla et al., 1996) , involved in the generation of tumor provisional matrix and to neoangiogenesis (Castellani et al., 1994) . Furthermore, we have previously identified an alternatively spliced IL-15 mRNA isoform, preferentially expressed in some human tumors (Meazza et al., 1996 (Meazza et al., , 1997 , encoding for a nonsecretable IL-15 protein bearing a signal peptide (SP) of 21 amino acids, shorter and less hydrophobic than the previously reported IL-15 SP (48 aa) (Onu et al., 1997; Gaggero et al., 1999) . Further studies in transgenic mice, expressing either one IL-15 isoform, showed that only the 48SP-IL-15 is capable to potentiate protective responses against pathogens, while the 21SP-IL15 appeared immune-suppressive (Nishimura et al., 2000) . Thus, it is conceivable that during neoplastic transformation alterations of the splicing may favor the production of proteins involved in tumor progression (Galmozzi et al., 2001) or in tumor escape from immune system. The altered capability to produce biologically active forms of IL-15 or of IL-18 may perhaps confer an immune privilege to tumors during neoplastic transformation. Indeed tumor cells genetically engineered to express biologically active IL-15 (Meazza et al., 2000) or IL-18 (Osaki et al., 1999; Tatsumi et al., 2002) show a reduction in their tumorigenicity in experimental tumor models and induce immune reactions, in relationship to the induction of IFNg production (Coughlin et al., 1998; Meazza et al., 2000; Tatsumi et al., 2002) . IFNg is not spontaneously secreted by ovarian tumors (Nash et al., 1998) , which release several other cytokines involved in tumor progression or autocrine loops (Naylor et al., 1993; Wu et al., 1993; Hartenbach et al., 1997; Mesiano et al., 1998) . In addition, IFNg has been shown to exert antitumor effects on ovarian cancer both in vitro (Kost et al., 1999) and in vivo (Windbichler et al., 2000) , further suggesting that IFNg release from lymphoid cells triggered by biologically active IL-18 could inhibit ovarian tumor growth. The finding that D3pro-IL-18 cannot be cleaved by caspase-1 or -4 to a biologically active form, but retained the capacity to physically interact with caspase-1, suggested that it may inhibit classical pro-IL-18 processing. The real ability of D3pro-IL-18 to act as an intracellular inhibitor of IL-18 processing may, however, depend on its relative concentration and affinity for these caspases, which remain to be determined. Nevertheless, in the OVCAR-3 ovarian cancer cell line, which express caspase-1 and -4, no IL-18 processing could be observed, and a substantial amount of IL-18 appeared to be resistant to in vitro processing by an excess of caspase-1. Thus, it is likely that the alternate splicing, leading to the generation of D3pro-IL-18, may represent a regulatory mechanism that inhibits the production of biologically active IL-18 in some ovarian tumors. In this context, it should be outlined that similar to the IL-1b/IL-1R system, the IL-18/IL-18R system also has several natural inhibitors which may negatively regulate the IL-18 biological activity, protecting the organism from unappropriate IL-18-mediated damage (Novick et al., 1999; Kim et al., 2000; Young et al., 2000; Xiang and Moss, 2001; Bufler et al., 2002) . Thus, a soluble IL-18 binding protein (BP), which prevent binding of mature IL-18 to its receptor, and inhibits IL-18 biological activity has been identified Figure 6 D3pro-IL-18 binds to caspase-1. D3pro-IL-18 can form complexes with caspase-1. A cell lysate from Neuro2a expressing D3pro-IL-18 was incubated for 30 min at 371C in the presence or absence of recombinant caspase-1 and D3pro-IL-18 was then immunoprecipitated using a rabbit anti-IL-18 polyclonal Ab and protein-A. Immunoprecipitated molecules were split into two aliquots, resolved by 14% SDS-PAGE and blotted. One blot was stained with anti-caspase-1 goat Ab, and the other with anti-IL-18 mAb. 1 mg of rabbit Ig was run in a control lane Caspase-1 and -4-resistant variant of pro-IL-18 A Gaggero et al (Novick et al., 1999) . Four isoforms of this IL-18 BP, displaying differential ability to bind and inhibit IL-18 activity exists in humans (Kim et al., 2000) , and a poxvirus-encoded IL-18 BP analog displaying similar inhibitory activity has been described (Xiang and Moss, 2001 ). In addition, a IL-1b homologue (IL-1F7b) has been reported to interact with IL-18 BP and cooperate in blocking IL-18 activity (Bufler et al., 2002) .
In conclusion, we propose that the generation of the alternative D3pro-IL-18 isoform represents a negative regulatory mechanism, which may downregulate production of mat-IL-18 in ovarian tumors. It is conceivable that this regulatory mechanism may be active not only in tumors, where it may represent a tumor escape mechanism, but also in other conditions.
Materials and methods

Cell lines and cultures
Human ovarian tumor cell lines used in this study were: IGROV-1, A2780, OC314 and OVCAR-3. Neuro2a murine cell line was used for stable transfections of IL-18 cDNAs. IGROV-1 cell line was kindly provided by Dr J Be´nard (Istitute Gustave Roussy, Paris, France), OC314 by Dr A Alama (IST, Genoa, Italy); the remaining cell lines were from ATCC (Rockville, MD, USA). All these cell lines were mycoplasma free at the moment of the experiments and were cultured in RPMI-1640 (Biowhittaker) medium supplemented with 10% heat-inactivated FCS (Seromed) and 200 mM Lglutamine (Biowhittaker). Ascitic fluid from stage III-IV serous ovarian carcinoma patients was collected by paracentesis in sterile 500 ml bottles containing 5000 U heparin (Wang et al., 2002) . All human materials were obtained with informed consent from patients. Ovarian surface epithelium was scraped from the surface of normal ovaries of patients undergoing surgery for benign or malignant gynecological diseases other than ovarian carcinoma. Ovarian surface epithelium cells were maintained in culture for 3-5 passages in 199-MCDB105 medium supplemented with 15% FCS and 25 mg/ml gentamicin as described (Kruk et al., 1994) . Cell origin was confirmed by immunohistochemistry.
RT-PCR analysis of IL-18 and caspase mRNAs expression
Total RNA was isolated using RNAzol B isolation reagent (Cinna Biotecx, Houston, TX, USA), according to the manufacturer's instructions. In all, 2 mg of RNA was reverse transcribed to cDNA using 0.5 mg oligo (dT) 12-18 primers, 20 U RNasin, 1 mM each dNTP and 200 U M-MLV reverse transcriptase in a final volume of 20 ml. A total of 2 ml of the cDNA were amplified by PCR in a final volume of 25 ml in the presence of 1 mM each dNTPs, 10 Â PCR Buffer, 1 U of AmpliTaq and of 1 mM of the following primers: upper primer for hIL-18: GCAAGCTTGAATCTAAATTA; lower primer for IL-18: GCTAGTCTTCGTTTTGAACAG; upper primer for hIL-18 exon 3 flanking region: GCATCAACTTTGTGG CAATG; lower primer for hIL-18 exon 3 flanking region: CAAAGTAATCTGATTCCAGG; upper primer for hcaspase-1: GGTCCTGAAGGAGAAGAGAA; lower primer for hcaspase-1: AGGCCTGGATGATGATCACC; upper primer for hcaspase-3: TGAGCCATGGTGAAGAAGG; lower primer for hcaspase-3: AACCCGGGTAAGAATGTGC; upper primer for hcaspase-4: GGCAGAAGGCAACCACAGAAA; lower primer for hcaspase-4: TTCCTCGGAGGCAGAT GGTC; upper primer for b-actin: GGCATCGTGATGGA CTCCG; lower primer for b-actin: GCTGGAAGGTGGACA GCGA.
The amplification was performed in a Perkin-Elmer 2400 DNA thermal cycler for 30 cycles with a final extension at 721C for 7 min. In total, 10 ml of amplified products was analysed on 1.5 or 4% agarose gels and stained with ethidium bromide.
Plasmid assembly and Neuro2a cell transfection
The whole ORF of human IL-18 was amplified by RT-PCR from total RNA extracted from OVCAR-3 cells using the following primers: upper CATACGAATTCAGGAATAAA-GATGGCTGCT and the above described lower (30 cycles: 15 s at 951C, 15 s at 561C, 20 s at 721C with a final extension at 721C for 5 min). cDNA was first subcloned in the PCR2.1 vector using the TOPO-TA cloning system (Invitrogen), sequenced and then subcloned into the p-IRES1neo expression plasmid (Clontech). Neuro2a murine neuroblastoma cells were transfected with 10 mg of pro-IL-18pIRES1neo, or of D3pro-IL-18pIRES1neo or empty vector using cationic liposomes (Fugene, Roche, Milano, Italy) . Stable transfectants and clones were obtained by limiting dilution in medium containing G418 (500 mg/ml) and were then screened for IL-18 mRNA expression by RT-PCR as above described.
Western blot analysis of intracellular and released IL-18
Cells (2 Â 10 6 ) were collected and centrifuged at 1400 r.p.m. for 5 min. Cell pellets were washed twice with medium without serum and twice with phosphate-buffered saline (1 Â PBS). Cells were resuspended in 25 ml of lysis buffer (10 mM Tris HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 0,5%Triton X-100 and 0.4 mM PMSF) and lysed for 30 min on ice. The cell debris were removed by centrifugation at 13 000 g. Samples were mixed with the same volume of 2 Â loading buffer containing 2% SDS and 10% b-mercaptoethanol, boiled for 3 min and analysed on a 14% polyacrylamide gel. In total 20 ng of recombinant mature hIL-18 was run in a parallel lane as positive control (Pepro Tech EC Ltd, England). The gel, after soaking in Towbin transfer buffer, was blotted onto a Hybond-C membrane (Amersham GB) at 250 mA for 2 h at 41C. The blot was saturated overnight in Tween-Tris buffered saline (TTBS) containing 10% nonfat dry milk and then incubated for 2 h in 1 Â PBS with 2% BSA containing 2 mg/ml of the rabbit anti-human IL-18 antibody (Pepro Tech EC Ltd, England). After washings with TTBS 1 Â , the blot was stained with 1 : 2000 dilution of peroxidase-conjugated anti-rabbit Ig antiserum (Dako, Denmark) for 2 h. Bands were visualized by the enhanced chemoluminescence (ECL) system according to the manufacturer's instructions (Amersham, GB).
For the evaluation of cell-released IL-18, 1 Â 10 6 aliquots of Neuro2a-pro-IL-18 or -D3pro-IL-18 transfectants were collected, washed with medium without serum and cultured in RPMI-1640 (Hyclone, Cramlington, UK) medium supplemented with 200 mM L-glutamine (Genzyme, Cambridge, MA, USA) and 1 Â Nutridoma-HU (Roche, Italy). After 72 h of culture, cell supernatants were collected and precipitation of secreted proteins was performed with 10% TCA at 41C for 12 h. Protein pellets were washed three times with cold acetone, dried, resuspended in 25 ml of water and treated in the same way as lysates (see above) for Western blot analysis.
In vitro caspase digestion assays
In all, 2 Â 10 6 IGROV-1, OVCAR-3, Neuro2a and Neuro2a-pro-IL-18 or D3pro-IL-18 transfectant cells were collected and centrifuged at 1400 r.p.m. for 5 min. Sample lysates were prepared as described for Western blot analysis using 15 ml of lysis buffer. The incubation with the indicated amount of the different active recombinant caspases (Calbiochem) was performed at 371C for 30 min and was followed by the addition of 20 U/ml of foy, a serine protease inhibitor (Lepetit Group). Samples were processed for Western blot analysis as described above.
Southern blot analysis of amplification products
Agarose gels were alkali blotted onto Hybond TM -N þ (Amersham Life Science, Buckinghamshire, UK) according to the manufacturer's instructions and hybridized with the oligonucleotide probes ATAGAAAACCTGGAA, AGCT-GAAGATGATG or GACAATACG CTTTAC (annealing, respectively, to RT-PCR products from D3pro-IL-18, classical pro-IL-18 or to both isoforms) labeled with g-32 P-ATP (Amersham) at the 5 0 ends using T4 polynuclotide kinase (Boehringer Mannheim, Germany). The labeled oligonucleotides were purified by 19% polyacrilamide gel electrophoresis. The hybridizations were carried out in a bath at temperatures about 151C under the TM estimated by the equation of Bolton and Mc Carthy (Molecular cloning, Sambrook, Fritsch, Maniatis), in a buffer containing 3 Â SSC, 0.5% SDS, 10% Denhardt's, 100 mg/ml denatured salmon sperm DNA. Stringent washings were carried out before exposure of the membranes to Hyperfilm (Amersham) for different periods (3-16 h) at -801C.
Immunoprecipitation of D3pro-IL-18/caspase-1 complexes Lysates from 6 Â 10 6 Neuro2a cells expressing D3pro-IL-18 were incubated for 30 min at 371C with or without 300 U of recombinant human caspase-1 (Calbiochem). A measure of 2 mg of rabbit anti-IL-18 polyclonal antibody (Peprotech) was added to each sample, mixed and incubated for 1 h in ice. Protein A-sepharose beads (30 ml) (Amersham Pharmacia Biotech) were added to each reaction and incubated at 41C for 2 h with gentle mixing. The pellets were washed twice with lysis buffer and resuspended in 50 ml of 1 Â gel loading buffer containing 2.5% 2-mercaptoethanol. Samples were heated at 1001C for 5 min, centrifuged and resolved by 14% SDS-PAGE (5 ml/lane). Recombinant human caspase-1 (80 ng) or a lysate (5 ml) from D3pro-IL-18-transfected Neuro2a cells were run in parallel lanes for positioning. Western blots were then probed with a goat anti-human caspase-1 polyclonal antibody (Merck Research Lab. Rahway, NY, USA) and with a mouse antihuman IL-18 monoclonal antibody (Pepro Tech EC Ltd, England), as described above. Finally, the blots were stained with 1 : 3000 dilution of peroxidase-conjugated anti-goat Ig antiserum (Dako, Denmark) or with 1 : 1500 dilution of peroxidase-conjugated anti-mouse Ig antiserum, respectively (Dako, Denmark), for 2 h.
